Urticaria – Landscape & Forecast – Disease Landscape & Forecast
Copy/Paste the key inputs from the product brochure, per guidance from Marketing.
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors for driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.
Questions answered
- What is the physician perspective on steroids and antihistamines for chronic urticaria? How frequently are these therapies prescribed?
- How do allergists and dermatologists diagnose and treat chronic urticaria, and how does treatment differ between specialists? Are inducible and spontaneous urticaria treated similarly, or is the treatment algorithm distinct?
- Which therapies are expected to have the biggest impact on the chronic urticaria market forecast? Will emerging therapies shift the treatment algorithm, or will biologics remain later-line treatments?
- How does Xolair (Novartis / Genentech), approved for chronic idiopathic urticaria in the United States, perform, and how will emerging biologics compare? How does its performance compare with that of frequently prescribed conventional therapies, including steroids and antihistamines?
Content highlights
Geographies: United States, EU5, Japan.
Primary research: 25 country-specific interviews with thought-leading allergists and dermatologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Number of chronic urticaria patients by country, including diagnosed and drug-treated patients
Forecast: 10-year, annualized, drug-level sales and patient share of key chronic urticaria therapies through 2029, segmented by brands/generics.
Emerging therapies: Phase III / PR: 2 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature material updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Urticaria - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- August 2023
- March 2023
- Q4 2022
- December 2022
- Q3 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Market outlook
- Key findings
- Market share of drug classes for chronic urticaria: 2021
- Market share of drug classes for chronic urticaria: 2031
- Chronic urticaria SWOT analysis
- Market drivers and constraints
- What factors are driving the market for chronic urticaria?
- What factors are constraining the market for chronic urticaria?
- Major-market sales of select therapies in chronic urticaria: 2021-2031
- Major-market patient share of select therapies in chronic urticaria: 2021-2031
- Drug-class-specific trends
- Major-market sales of omalizumab in chronic urticaria: 2021-2031
- Major-market sales of dupilumab in chronic urticaria: 2021-2031
- Major-market patient share of dupilumab in chronic spontaneous urticaria: 2021-2031
- Major-market patient share of dupilumab in chronic inducible urticaria: 2021-2031
- Major-market sales of remibrutinib: 2026-2031
- Major-market sales of benralizumab in chronic urticaria: 2026-2031
- Major-market patient share of montelukast in chronic urticaria: 2021-2031
- Major-market sales of antihistamines in chronic urticaria: 2021-2031
- Major-market sales of therapies used off-label in chronic urticaria: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Etiology
- Pathophysiology
- Differential diagnosis
- Forms of chronic inducible urticaria
- Key pathways and drug targets
- Cell types involved in chronic urticaria
- Disease overview
- Epidemiology
- Key findings
- Key updates
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed prevalent cases of chronic urticaria: 2021-2031
- Disease definition, methods, and sources used
- Total prevalent cases of chronic spontaneous urticaria: 2021-2031
- Disease definition, methods, and sources used
- Total 12-month prevalent cases of chronic inducible urticaria: 2021-2031
- Diagnosed prevalent cases of chronic spontaneous urticaria: 2021-2031
- Diagnosed prevalent cases of chronic inducible urticaria: 2021-2031
- Drug-treated prevalent cases of chronic spontaneous urticaria: 2021-2031 (thousands)
- Drug-treated prevalent cases of chronic inducible urticaria: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for chronic urticaria
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for chronic urticaria
- Current treatments used for chronic urticaria
- Market events impacting the use of key current therapies for chronic urticaria
- Advantages and disadvantages of second-generation H1 antihistamines
- Expert insight: second-generation H1 antihistamines
- Advantages and disadvantages of first-generation H1 antihistamines
- Expert insight: first-generation H1 antihistamines
- Advantages and disadvantages of Xolair
- Expert insight: Xolair
- Advantages and disadvantages of montelukast
- Expert insight: montelukast
- Advantages and disadvantages of immunosuppressants
- Expert insight: immunosuppressants
- Advantages and disadvantages of TNF-u03b1 inhibitors
- Expert insight: TNF-u03b1 inhibitors
- Advantages and disadvantages of off-label therapies
- Medical practice
- Overview
- Factors influencing drug selection in chronic urticaria
- Treatment decision tree for chronic urticaria: United States
- Treatment decision tree for chronic urticaria: Europe
- Treatment decision tree for chronic urticaria: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in chronic urticaria
- Top unmet needs in chronic urticaria: current and future attainment
- Expert insight: unmet need in chronic urticaria
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for chronic urticaria
- Dupilumab profile
- Key ongoing clinical trials of dupilumab in the treatment of chronic urticaria
- Analysis of the clinical development program for dupilumab
- Expert insight: dupilumab
- Expectations for launch and sales opportunity of dupilumab in chronic urticaria
- Remibrutinib profile
- Key ongoing clinical trials of remibrutinib in the treatment of chronic urticaria
- Analysis of the clinical development program for remibrutinib
- Expert insight: remibrutinib
- Expectations for launch and sales opportunity of remibrutinib in chronic urticaria
- Benralizumab profile
- Key ongoing clinical trials of benralizumab in the treatment of chronic urticaria
- Analysis of the clinical development program for benralizumab
- Expert insight: benralizumab
- Expectations for launch and sales opportunity of benralizumab in chronic urticaria
- Early-phase pipeline analysis
- Select compounds in early-phase development for chronic urticaria
- Key discontinuations and failures in chronic urticaria
- Key discontinuations and failures
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in chronic urticaria: United States
- General reimbursement environment: United States
- Key market access considerations in chronic urticaria: EU5
- General reimbursement environment: EU5
- Key market access considerations in chronic urticaria: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Chronic urticaria bibliography
- Key findings
Shubhendu Ghosh, Ph.D., Senior Healthcare Research & Data Analyst, Immune and Inflammation. Dr. Ghosh’s focus is the asthma and urticaria therapy markets. Previously, he was an associate editor at Nature Structural & Molecular Biology and a copy editor at Nature Medicine. He was also a scientific and developmental editor at Nature Research Editing Service. He holds a Ph.D. in biomedical sciences from the University of Massachusetts Medical School, a B.Sc. in microbiology from Delhi University, and an M.Sc. in biotechnology from Madurai Kamaraj University.